



## Increasing Resveratrol Effectiveness as an Anti-cancer Agent for Human Therapy

**James D Weinstein\***

*Professor of Neuroscience, John C. Edwards Medical School, Marshall University (Retired), Huntington, West Virginia, USA*

**\*Corresponding Author:** James D Weinstein, Professor of Neuroscience, John C. Edwards Medical School, Marshall University (Retired), Huntington, West Virginia, USA.

**Received:** August 20, 2018; **Published:** September 12, 2018

Resveratrol, a polyphenol produced by certain plants is shown, quoting Aggarwal, to “exhibit anti-cancer properties in a wide variety of tumor cells, including lymphoid and myeloid cancers; multiple myeloma; cancers of the breast, prostate, stomach, colon, pancreas and thyroid; melanoma; head and neck squamous cell carcinoma; ovarian and cervical carcinoma” [1]. The inhibition of multiple types of cancer has also been reported by Niles and Rankin, studies being done with tissue culture and rodent cancer models [2].

Unfortunately because of a low bioavailability free resveratrol may have a limited effectiveness for human cancer therapy due to inadequate tissue levels of the drug for cancer inhibition [2,3]. Resveratrol in the plasma is rapidly eliminated from the body after sulfate and glucuronic acid conjugation of the phenolic groups of the resveratrol [3]. This problem can be circumvented by the acetylation of the three hydroxyl groups of resveratrol which blocks the conjugation with the sulfates and glucuronic acids and subsequent rapid elimination of these resveratrol metabolites.

It has been shown in two types of cancers that the acetylated resveratrol conjugates retain the cytostatic and cytotoxic activities of free resveratrol [4,5]. Presuming this activity is present for other cancer types and with the increased plasma longevity of the conjugates it is likely that they will have an increased anti-cancer activity compared to administering readily eliminated free resveratrol. The latter can presumably be released in the tissues from the resveratrol conjugates to the active free resveratrol.

In order to maintain the conjugate linkage to enhance its tissue uptake treatment with caffeine can be employed [6].

The toxicity of the conjugate as it is delivered into tissues must be determined in animal studies in consideration of subsequent human trials.

### Bibliography

1. Aggarwal BB, *et al.* “Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies”. *Anticancer Research* 24.5A (2004): 2783-2849.
2. Niles RM and Rankin GO. “Resveratrol, A phytoalexin with a multitude of anti-cancer activities”. *Nutrition and Cancer* (2012): 3-14.
3. Walle T. “Bioavailability of resveratrol”. *Annals of the New York Academy of Sciences* 1215 (2011): 9-15.
4. Colin D, *et al.* “Antiproliferative activities of resveratrol and related compounds in human hepatocyte derived HepG2 cells are associated with biochemical cell disturbance revealed by fluorescence analysis”. *Biochimie* 90.11-12 (2008): 1674-1684.
5. Marel A-K. “Inhibitory effects of trans-resveratrol analogues molecules on the proliferation and the cell cycle progression of human colon tumor cells”. *Molecular Nutrition and Food Research* 52.5 (2008): 538-548.
6. Lachman L and Higuchi T. “Inhibition of hydrolysis of esters in solution by formation of complexes III. stabilization of tetracaine with caffeine”. *Journal of the American Pharmaceutical Association* 46.1 (1957): 32-36.

**Volume 2 Issue 7 October 2018**

© All rights are reserved by James D Weinstein.